Celcuity Inc.
CELCHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Celcuity Inc. (CELC) is listed under Biotechnology. At a $4.31B market cap, Celcuity Inc. ranks as a mid-cap company within healthcare. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Market Cap
$4.31B
Beta
0.16
P/E (TTM)
—
P/E (Fwd)
92.06
EPS (TTM)
$-3.91
EPS (Fwd)
$0.96
ROE
-275.2%
ROA
-37.1%
Cash
$387.1M
Total Debt
$323.4M
Free CF
-$110.8M
52W Change
550.3%
Annual Financials
Cash vs Debt
Celcuity Inc. holds $387.1M in cash against $323.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$110.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -275.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.16 suggests CELC is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Celcuity Inc. and its sector.